Granted Patent
B2
US 12,472,181 · App. 18/146,698 · Granted Nov 18, 2025
Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Inventors:
Steven Emiel Van Der Plas (Mechelen, BE); Oscar Mammoliti (Mechelen, BE); Sebastien Laurent Xavier Martina (Mechelen, BE); Pieter Isabelle Roger Claes (Gentbrugge, BE); Ghjuvanni Petru Diunisu Coti (Mechelen, BE); Denis Maurice Annoot (Romainville, FR); Miriam López Ramos (Romainville, FR); René Alexandre Galien (Romainville, FR); David Amantini (Romainville, FR); Réginald Christophe Xavier Brys (Mechelen, BE)
Assignee:
Galapagos NV
A61K31/506A61K31/444A61K31/4545A61K31/496A61K31/501A61K31/5355A61P35/00A61P37/06C07D471/04C07D519/00C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention discloses compounds according to Formula I: Wherein R 1 , L 1 , R 2 , L 2 , R 3 , Cy, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL12 and/or IL23 by administering the compound of the invention.
Claims (4)
1 . A compound according to Formula 38:
or a pharmaceutically acceptable salt thereof, solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof.
2 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to claim 1 .
3 . The pharmaceutical composition according to claim 2 , comprising a further therapeutic agent.
Assignments (5)
CHANGE OF NAME
Recorded Jun 4, 2026
From: GALAPAGOS
To: LAKEFRONT BIOTHERAPEUTICS
Reel/Frame 074845/0068 →
CORRECTIVE ASSIGNMENT TO CORRECT THE FOURTH INVENTOR'S EXECUTION DATE PREVIOUSLY RECORDED AT REEL: 062957 FRAME: 0957. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT .
Recorded Mar 29, 2023
From: MAMMOLITI, OSCAR; COTI, GHJUVANNI PETRU DIUNISU; MARTINA, SÉBASTIEN LAURENT XAVIER; CLAES, PIETER ISABELLE ROGER; VAN DER PLAS, STEVEN EMIEL; BRYS, REGINALD CHRISTOPHE XAVIER
To: GALAPAGOS NV
Reel/Frame 063189/0375 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 13, 2023
From: GALIEN, RENÉ ALEXANDRE; AMANTINI, DAVID; ANNOOT, DENIS MAURICE; LÓPEZ RAMOS, MIRIAM
To: GALAPAGOS SASU
Reel/Frame 062957/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 13, 2023
From: MAMMOLITI, OSCAR; COTI, GHJUVANNI PETRU DIUNISU; MARTINA, SÉBASTIEN LAURENT XAVIER; CLAES, PIETER ISABELLE ROGER; VAN DER PLAS, STEVEN EMIEL; BRYS, REGINALD CHRISTOPHE XAVIER
To: GALAPAGOS NV
Reel/Frame 062957/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 13, 2023
From: GALAPAGOS SASU
To: GALAPAGOS NV
Reel/Frame 062958/0114 →
Priority Claims (1)
GB 1717260
· Oct 20, 2017
· national
Continuity (2)
Continuation
16757189
References Cited (22)
US 9556153B1
· Clayton
· 2017
[cited by applicant]
WO 2007077949A1
· 2007
[cited by applicant]
WO 2008135785A1
· 2008
[cited by applicant]
WO 2013116291A1
· 2013
[cited by applicant]
WO 2015110378A1
· 2015
[cited by applicant]
Drugs.com. Ibuprofen. Retrieved from the Wayback Machine on Aug. 15, 2023, https://web.archive.org/web/20171020000614/https://www.drugs.com/ibuprofen.html. Published Oct. 20, 2017. (Year: 2017).
[cited by examiner]
Babon et al., The Molecular Regulation of Janus Kinase (JAK) Activation, Biochem. J., (2014), vol. 462, No. 1, pp. 1-13.
[cited by applicant]
Broekman et al., “Tyrosine Kinase Inhibitors: Multi-Targeted or Single-Targeted?”, World Journal of Clinical Oncology, (2011), vol. 2, No. 2, pp. 80-93.
[cited by applicant]
Da et al., “Discovery of Mer Kinase Inhibitors by Virtual Screening Using Structural Protein-Ligand Interaction Fingerprints”, Bioorganic & Medical Chemistry, (2015), vol. 23, No. 5, pp. 1096-1101.
[cited by applicant]
Fabian et al., “A Small Molecule-Kinase Interaction Map for Clinical Kinase Inhibitors”, Nature Biotechnology, (2005), vol. 23, No. 3, pp. 329-336.
[cited by applicant]
Gillooly et al., “BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of Tyk2, Blocks IL-12, IL-23 and Type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Systemic Lupus Er…
[cited by applicant]
Neubauer et al., “Jak2 Deficiency Defines an Essential Developmental Checkpoint in Definitive Hematopoiesis”, Cell, (1998), vol. 93, pp. 397-409.
[cited by applicant]
O'Shea et al., “JAKs and STATs in Immunoregulation and Immune-Mediated Disease”, Immunity Review, (2012), vol. 36, pp. 542-550.
[cited by applicant]
Parganas et al., Jak2 is Essential for Signaling Through a Variety of Cytokine Receptors, Cell, (1998), vol. 93, pp. 385-395.
[cited by applicant]
Schwartz et al., “Type I/II Cytokines, JAKs, and New Strategies for Treating Autoimmune Disease”, Nature Reviews—Rheumatology, (2016), vol. 12, pp. 25-36.
[cited by applicant]
Sohn et al., “A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors”, The Journal of Immunology, (2013), vol. 191, pp. 2205-2216.
[cited by applicant]
Vainchenker et al., JAKs in Pathology: Role of Janus Kinases in Hematopoietic Malignancies and Immunodeficiencies, Seminars in Cell & Developmental Biology, (2008), vol. 19, pp. 385-393.
[cited by applicant]
International Search Report and Written Opinion for PCT/EP2018/077677 mailed Jan. 22, 2019.
[cited by applicant]
Oscar Mammoliti et al., “Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases”, Journal of Medicinal Chemistry, 2024, vol. 67, pp. 8545-8568, https://do…
[cited by applicant]